China Regenerative Medicine International Ltd
HKEX:8158
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (7.4), the stock would be worth HK$0.06 (86% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 51.7 | HK$0.41 |
0%
|
| 3-Year Average | 7.4 | HK$0.06 |
-86%
|
| Industry Average | 10.3 | HK$0.08 |
-80%
|
| Country Average | 9.3 | HK$0.07 |
-82%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| HK |
C
|
China Regenerative Medicine International Ltd
HKEX:8158
|
123.2m HKD | 51.7 | 4.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 24.1 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 28.1 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 18.4 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 31.5 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 14.1 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 142.2 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 20.6 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.7 |
| Median | 9.3 |
| 70th Percentile | 16.9 |
| Max | 20 343.5 |
Other Multiples
China Regenerative Medicine International Ltd
Glance View
China Regenerative Medicine International Ltd. is an investment holding company, which engages in in research and development of medical and healthcare products. Along with subsidiaries, the Company operates its business through four segments. The Medical Equipment segment is involved in trading of medical equipments. The Tissue Engineering segment is involved in production and sale of tissue engineering products. The Cosmetic and Others segment is involved in production and sales of cosmetic, healthcare and other products. The Stem Cell segment is involved in research of cellular and stem cell therapy, sales and distribution of stem cell medical equipment, as well as the provision of other services.
